Physician profile
Isabel Padilla
NPI 1447644950
$2,131.33
in general payments reported to CMS, 2019-2025
23 companies · $18.97 in 2025
The $18.97 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $29.66 · 2021: $38.05 · 2022: $317 · 2023: $1,462 · 2024: $19.25 · 2025: $18.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,500.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $559.51 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $415.12 | 2022-2023 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $250.67 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $173.26 | 2022-2023 | Mounjaro, Jardiance, Emgality |
| Inspire Medical Systems, INC. | $101.08 | 2023 | Inspire |
| Amgen INC. | $64.64 | 2023 | Repatha, Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $62.46 | 2023 | |
| Pfizer INC. | $57.26 | 2023 | |
| Astellas Pharma US INC | $50.42 | 2023 | Veozah |
| Vanda Pharmaceuticals INC. | $48.15 | 2022-2023 | Hetlioz |
| Abbvie INC. | $45.75 | 2022-2023 | |
| Genentech USA, INC. | $40.68 | 2020-2021 | |
| Exact Sciences Corporation | $34.52 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.46 | 2023 | Ofev |
| Pulmonx Corporation | $32.33 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $31.72 | 2023 | Edarbi, Edarbyclor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.02 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $19.86 | 2023 | Xarelto |
| Dexcom, INC. | $19.25 | 2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $16.49 | 2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $16.47 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.21 | 2023 | |
| Paratek Pharmaceuticals, INC. | $14.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabel Padilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.